Protagonist Therapeutics
PTGX · NASDAQ
Bulios Fair Price
$111.83
22.2% downside
Trenutna cena
$143.73
Po podatkih Bulios Fair Price je delnica PTGX trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
AI poročilo o poslu, financah, vrednotenju, razpoloženju, novicah in tveganjih - napisano v nekaj minutah.
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapeutics for hematological disorders and inflammatory diseases. Their lead candidate, rusfertide, is a synthetic mimetic of the hormone hepcidin, currently in Phase 3 clinical trials for the treatment of polycythemia vera, a rare blood disorder. In 2024, the company entered into an agreement with Takeda Pharmaceutical, receiving an upfront payment of $300 million for global commercialization rights to rusfertide outside the U.S.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Dinesh V. Patel
Employees
141
Headquarters
Newark
Prihajajoči dogodki
Earnings
Upcoming earnings report